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Specific cytotoxic T-lymphocyte (CTL) responses to nucleocapsid of infectious bronchitis virus (IBV) were
identified by using target cells infected with a Semliki Forest virus (SFV) vector. Effector cells for CTL assays
were collected from chickens infected with the Gray strain of IBV or inoculated with a DNA plasmid encoding
nucleocapsid proteins. IBV-specific CTL epitopes were mapped within the carboxyl-terminal 120 amino acids
of the nucleocapsid protein. CTL lysis of target cells infected with SFV encoding nucleocapsid was major
histocompatibility complex restricted and mediated by CD81 T cells. In addition, splenic T cells collected from
chickens inoculated in the breast muscle with a DNA plasmid encoding this CTL epitope(s) recognized target
cells infected with wild-type virus or an SFV vector encoding nucleocapsid proteins. CTL activity of splenic T
cells collected from chicks immunized with a DNA plasmid encoding CTL epitopes was cross-reactive, in that
lysis of target cells infected with serologically distinct strains of IBV was dose responsive in a manner similar
to that for lysis of target cells infected with the homologous strain of IBV. Furthermore, chickens immunized
with a DNA plasmid encoding a CTL epitope(s) were protected from acute viral infection.
Cytotoxic T-lymphocyte (CTL) responses provide a major
defense mechanism for elimination of virus-infected cells, and
in some cases CTL have been able to confer complete protec-
tion even in the absence of an antibody response (2, 18). CTL
recognize endogenously expressed peptide in association with
major histocompatibility complex (MHC) class I molecules (4,
5). As CTL often recognize conserved determinants of the
virus, CTL epitopes should be valuable in designing effective
vaccines (21).
Infectious bronchitis virus (IBV) is a prototype of the Coro-
naviridae family. The virion is composed of a positive-stranded
genomic RNA, a lipid-containing membrane, and four struc-
tural proteins (17, 25). In addition to the internally localized
nucleocapsid protein, the virion is composed of the spike and
membrane proteins and a third, smaller envelope protein (3, 7,
9, 10, 19). IBV causes morbidity in all ages of chickens and high
mortality in chickens that are less than 6 weeks old (13, 15).
IBV continues to cause major economic losses in the poultry
industry worldwide, in spite of the widespread use of live at-
tenuated vaccines. Control of IBV is difficult because numer-
ous field isolates differ antigenically from vaccine serotypes
(32).
Most studies of IBV immunity have focused on humoral
immune responses to spike protein. However, by generating
antigenic variants of the S protein, IBV can avoid elimination
by neutralizing antibody (8, 14, 16). In a previous study, we
reported evidence that IBV-specific CTL were critical in re-
solving early viral infection in IBV target organs (26). Studies
with other viral infections indicate that the internal, nonglyco-
sylated viral antigens contribute to the induction of protective
immunity by generating CTL (1, 12, 23). Until now, CTL re-
sponses to IBV nucleocapsid protein have not been reported,
but CD4 epitopes within the IBV N protein have been identi-
fied in the mouse (6). In the present study, we report for the
first time that specific CTL epitopes to nucleocapsid of IBV
can play a central role in protecting chickens from acute viral
challenge.
MATERIALS AND METHODS
Experimental animals. Embryonated eggs of inbred (B12/B12) and outbred
(R68C) chickens were obtained from Hy-VAC (Adel, Iowa) and SPAFAS In-
corporated (Preston, Conn.), respectively. Eggs were hatched in our laboratory,
and chickens were housed in a specific-pathogen-free environment at the Lab-
oratory Animal and Resources Facility, Texas A & M University, College Sta-
tion.
Viral source. The nephropathogenic Gray, Arkansas, and Mass41 strains of
IBV were propagated by inoculating the allantoic sac of 11-day-old chicken
embryos. Allantoic fluid harvested 36 h postinfection (p.i.) was collected as a
source for viral inoculation (28). Tissue culture-adapted viruses were propagated
in an established chicken kidney (CK) cell line before harvesting 48 h p.i. (26).
Generation of recombinant SFV vectors. IBV genomic RNA was prepared as
described by Sneed et al. (28). First-strand cDNA synthesis was carried out as
described in the Superscript manual (GIBCO BRL, Grand Island, N.Y.), using
a 39-end primer (59GTTGGATCCGAGTTCATTCTCACCTAAAGC39) of IBV
genomic RNA before proceeding to amplification. PCR was performed by using
the appropriate primers (Table 1) for synthesizing overlapping fragments of the
nucleocapsid gene with the following reaction conditions: primary denaturation
at 94°C for 5 min, annealing at 55°C for 30 s, extension at 72°C for 45 s, and
subsequent denaturation at 94°C for 1 min. A total of 35 cycles were used, with
a final extension step of 7 min at 72°C. Resulting PCR products were digested
with BamHI before ligation into a Semliki Forest virus (SFV) plasmid pSFV1
also digested with BamHI (GIBCO BRL). After transformation, Escherichia coli
colonies were screened for inserts by miniscale preparation (24) before checking
for correct orientation by ABI PRISM dye terminator cycle sequencing (Perkin-
Elmer). Packaging of SFV recombinants was carried out as specified by the
manufacturer (GIBCO BRL).
Flow cytometric analysis of infected cells. CK cells (2 3 106) were infected at
a multiplicity of infection of 2.0 with recombinant SFV encoding IBV nucleo-
capsid proteins or transfected by electroporation (250 V, 80 mF) with 20 mg of
recombinant DNA plasmids before incubation for 24 or 36 h, respectively. The
cells were fixed with 1.8% formaldehyde and permeabilized in 0.1% Nonidet
P-40 (Sigma). The cells were then incubated with a 1:50 dilution of mouse
anti-IBV polyclonal antibody in fluorescence-activated cell sorting (FACS)
buffer (phosphate-buffered saline containing 1% bovine serum albumin and
0.1% sodium azide) on ice for 30 min before being washed with FACS buffer five* Corresponding author.
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times. The cells were then incubated with a 1:50 dilution of fluorescein isothio-
cyanate-labeled goat anti-mouse immunoglobulin G (IgG) in FACS buffer on ice
for 30 min before being washed five times with FACS buffer. The reaction
samples were resuspended to 106 cells per ml in 1.8% formaldehyde and ana-
lyzed with a FACScalibur (Becton Dickinson, San Jose, Calif.).
Generation of target cells. CK cells (2 3 106) were infected either with the
Gray strain of IBV (106 50% egg infective doses (EID50) for 2 days or with SFV
vectors (multiplicity of infection of 2.0) for 12 h before being resuspended in 400
ml of CTL assay medium (RPMI 1640 supplemented with 2% [vol/vol] chicken
serum). CK cells were labeled with 300 mCi of Na251CrO4 for 90 min, washed
three times, and resuspended in CTL assay medium at a final concentration of
2 3 105 cells per ml.
Preparation of effector cells. Splenocytes from IBV-infected or uninfected
chickens or splenocytes from chickens inoculated with a recombinant plasmid
encoding IBV nucleocapsid were used as the source of effector cells. Spleens
from six chickens at 10 or 13 days p.i. were collected and pooled as described
previously (26) and then stimulated in vitro with irradiated IBV-infected synge-
neic CK cells or irradiated N-SFV-infected syngeneic CK cells for 8 or 10 days
(3,000 rads) before use as CTL effector cells. The CD41 and CD81 lymphocytes
were also separated before use as CTL effector cells (26).
CTL assay. Splenic lymphocytes were tested for cytotoxic activity against
syngeneic and allogeneic target cells. To achieve various effector-to-target cell
ratios, effector cells were diluted in 96-well round-bottom microtiter plates in
100-ml volumes per well, and 100 ml of 2 3 104 target cells infected with IBV or
recombinant SFV encoding nucleocapsid genes was added to each well. Micro-
titer plates were centrifuged at 100 3 g for 5 min before incubation for 4 h at
40°C. After centrifugation at 600 3 g for 10 min, 100-ml aliquots of supernatants
in triplicate samples were collected for determining 51Cr release, using a gamma
radiation counter (Cobra Autogamma; Canberra Packard). Percent specific lysis
equaled (E 2 S/M 2 S) 3 100, where E is the mean of three test wells, S is the
mean of spontaneous release from the three target cells without effector cells,
and M is the mean maximal release from the three target cells with 3% Triton
X-100. The spontaneous chromium release of target cells was less than 20% of
the total chromium release in all experiments.
Construction of a recombinant DNA plasmid. The pTargeT mammalian ex-
pression vector (Promega, Madison, Wis.) was digested with restriction enzyme
BamHI and mixed with the Nd or Ne fragment of the IBV nucleocapsid gene
(Table 1) cut from the SFV plasmid with BamHI at a vector/insert molar ratio of
1:3 before ligation with T4 DNA ligase (Promega). After transformation by heat
shock (Invitrogen, San Diego, Calif.), E. coli colonies were screened for inserts
by miniscale preparation, and then the correct orientation was determined by
ABI PRISM dye terminator cycle sequencing (Perkin-Elmer).
DNA inoculation. The breast muscles of 5-day-old chickens were injected with
200 ml of a solution containing 0.25% bupivacaine-HCl (Sigma Chemical Co., St.
Louis, Mo.), using a 25-gauge needle (32), 2 days before 150 mg of each DNA
construct in phosphate-buffered saline was injected into the same location. Four
days after the first DNA inoculation, the second inoculation was administered to
the same site. Four days later, the chickens were challenged with 106 EID50 of
IBV Gray strain and examined for signs of clinical illness such as coughing,
sneezing, dyspnea, ataxia, or death. Lungs and kidneys were collected from the
chickens immunized with plasmid pTargeT encoding the Nd or Ne nucleocapsid
fragment and challenged with the Gray strain of IBV at 5 days p.i. Viral titers
were determined as described previously (26).
RESULTS
IBV-specific CTL lysed target cells expressing nucleocapsid
proteins. SFV vectors were used to generate target cells ex-
pressing individual viral polypeptides. Reverse transcription-
PCR cDNA products generated for each fragment as shown in
Fig. 1 were ligated into the vector. The corresponding con-
structs were designated N-SFV, Na-SFV, Nb-SFV, Nc-SFV,
Nd-SFV and Ne-SFV. CK cells infected with SFV vectors
encoding nucleocapsid polypeptides were analyzed for expres-
sion of individual proteins by flow cytometry. More than 90%
of the CK cells expressed IBV nucleocapsid polypeptides (Fig.
2A).
Effector cells collected from spleens of chicks infected with
the Gray strain of IBV 10 days p.i. were stimulated in vitro for
10 days with irradiated IBV-infected syngeneic CK cells before
use in CTL assays. CTL from infected chickens induced lysis of
target cells infected with wild-type virus or recombinant SFV
vectors encoding the whole nucleocapsid protein in a dose-
responsive manner. However, the lysis of target cells infected
with SFV alone by CTL from infected chicks was minimal (Fig.
3A). Effector cells from spleens of uninfected chickens caused
minimal lysis of target cells expressing the entire nucleocapsid
protein. These results indicate that at least one IBV-specific
CTL epitope exists in the nucleocapsid protein.
CTL lysis of target cells expressing IBV nucleocapsid pro-
tein was MHC restricted and mediated by CD81 T cells. The
in vitro-stimulated T cells induced lysis of syngeneic target cells
expressing whole nucleocapsid with maximum chromium re-
lease of 42% at an effector/target cell ratio of 45:1. In contrast,
effector cells did not lyse the allogeneic CK cells expressing
whole nucleocapsid or the uninfected syngeneic target cells
(Fig. 3B).
Depletion of CD41 T cells from in vitro-stimulated T cells
lysed syngeneic target cells expressing nucleocapsid proteins in
a dose-responsive manner similar to that for the undepleted
effector cell population, whereas depletion of CD81 T cells
reduced CTL activity as much as 75%. The residual CTL
activity could be caused by the presence of natural killer cells
or residual CD81 T cells (Fig. 3C). Depletion of T-cell sub-
populations was confirmed by flow cytometry (data not shown).
The IBV-specific CTL epitope mapped to the carboxyl-ter-
minal 120 amino acids of nucleocapsid. To locate IBV-specific
CTL epitopes in the nucleocapsid, the amino-terminal 172
amino acids and carboxyl-terminal 238 amino acids were ex-
FIG. 1. Diagram of nucleocapsid constructs. Each labeled fragment was am-
plified from cDNA of genomic RNA by using appropriate primers (Table 1). The
resulting PCR products were cloned into an SFV vector or pTargeT DNA vector,
using BamHI cloning sites.
TABLE 1. Primers of N fragments
N frag-
ment
Primer sequence
Forward Reverse
N 59CGCGGATCCGCACCATGGCAAGCGGTAAGG39 59GTTTGGATCCGAGTTCATTCTCACCTAAAGC39
Na 59CGCGGATCCGCACCATGGCAAGCGGTAAGG39 59CGCGGATCCGCATGCTGCTGTTGATCTTCCACTCC39
Nb 59CGCGGATCCGCACCATGTTCATCAGCAGCATCTAGT39 59GTTTGGATCCGAGTTCATTCTCACCTAAAGC39
Nc 59CGCGGATCCGCACCATGTCATCAGCAGCATCTAGT39 59CGCGGATCCGCATGTTTGGGCGTCACTCTACTTCCAAA39
Nd 59CGCGGATCCGCACCATGCTTCAAACCAGATGGGCTGC39 59GTTTGGATCCGAGTTCATTCTCACCTAAAGC39
Ne 59CGCGGATCCGCACCATGGCAAGCGGTAAGG39 59CGCGGATCCGCATGTTTGGGCGTCACTCTACTTCCAAA39
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pressed in target cells infected with Na-SFV and Nb-SFV (Ta-
ble 1). Splenic T cells collected from IBV-infected chickens
were stimulated in vitro with irradiated IBV-infected CK cells
for 8 days before use as CTL effector cells. Effector cells lysed
target cells infected with both N-SFV and Nb-SFV with a
maximum of 60% at an effector/target ratio of 40:1. Lysis of
target cells infected with Na-SFV was minimal. Therefore, the
IBV-specific CTL epitope(s) in the nucleocapsid protein re-
sides within carboxyl 238 amino acids (Fig. 4A).
To further map CTL determinants in the nucleocapsid, SFV
vectors encoding the overlapping fragments Nc, Nd, and Ne
were used to generate CK target cells. Splenic T cells from
IBV-infected chicks lysed syngeneic CK target cells infected
with IBV, N-SFV, and Nd-SFV in a dose-dependent manner
but not target cells expressing Nc-SFV or Ne-SFV or the un-
infected target cells (Fig. 4B). These results indicate that at
least one IBV-specific CTL epitope exists in Nd, the carboxyl-
terminal 120 amino acids of nucleocapsid.
IBV nucleocapsid-specific CTL were generated in vivo and
were cross-reactive. The nucleocapsid protein and polypep-
FIG. 2. (A) Detection by flow cytometry of viral protein expression in CK cells infected with SFV recombinants. CK cells were infected with SFV recombinants
N-SFV (a), Na-SFV (b), Nb-SFV (c), Nc-SFV (d), Nd-SFV (e), and Ne-SFV (f) before collection for analysis. Control cells were stained with normal mouse serum
and then with fluorescein isothiocyanate-labeled goat anti-mouse IgG antibody. (B) Detection of viral protein expression in CK cells transfected with pTargeT
recombinants, using flow cytometry. CK cells transfected with DNA recombinants Nd-pTargeT (a9) and Ne-pTargeT (b9) by electroporation were collected for analysis.
FIG. 3. (A) Lysis of target cells infected with SFV encoding whole nucleocapsid by IBV-specific CTL. Splenic T cells collected from chickens infected with the Gray
strain of IBV were stimulated in vitro with irradiated IBV-infected syngeneic CK cells before use as effector cells. Lysis of target cells infected with IBV is represented
by open squares, lysis of target cells infected with an SFV recombinant encoding whole nucleocapsid is represented by closed squares, lysis of target cells infected with
SFV alone is represented by closed triangles, and lysis of target cells infected with IBV by stimulated effector cells from uninfected chickens is represented by open
circles. (B) MHC-restricted lysis of target cells expressing nucleocapsid protein. Effector cells collected from IBV-infected chickens were stimulated in vitro before CTL
assay. Lysis of syngeneic CK cells infected with an SFV recombinant encoding nucleocapsid is represented by closed squares, lysis of heterologous CK cells infected
with an SFV recombinant encoding nucleocapsid is represented by closed diamonds, and lysis of uninfected syngeneic CK cells is represented by open circles. (C) CD81
T-cell-mediated lysis of target cells infected with an SFV recombinant encoding nucleocapsid. In vitro-stimulated splenic T cells were depleted of CD41 or CD81 T
cells before CTL assay. Lysis of target cells infected with an SFV recombinant encoding nucleocapsid protein by undepleted effector cells is represented by closed
squares, lysis of target cells infected with an SFV recombinant encoding nucleocapsid protein by effector cells depleted of CD41 T cells is represented by open circles,
and lysis of target cells infected with an SFV recombinant encoding nucleocapsid protein by effector cells depleted of CD81 T cells is represented by open triangles.
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tides expressed by the Nb and Nd sequences in target cells
were recognized by CTL from virus-infected chickens. In vivo
induction of CTL with endogenously expressed nucleocapsid in
the absence of other viral polypeptides was examined. pTargeT
DNA plasmids encoding Nd or Ne of the Gray strain of IBV
were constructed for inoculation of chicks. Transfection and
expression potential of pTargeT plasmids encoding Nd or Ne
were first examined in vitro in CK cells. More than 85% of
these cells were shown to express viral polypeptide (Fig. 2B).
Splenic T cells collected from chickens inoculated with
pTargeT plasmids were stimulated in vitro with irradiated
syngeneic CK cells infected with Nd-SFV or Ne-SFV for 8 days
before use as CTL effector cells. Nd-specific CTL were de-
tected in assays using target cells infected with the Gray strain
of IBV or Nd-SFV in a dose-responsive manner resulting in
maximum lysis of 45% at an effector/target ratio of 70:1 (Fig.
5A). In contrast, splenic T cells from uninoculated chickens or
chickens inoculated with Ne-pTargeT did not lyse target cells
infected with the Gray strain of IBV.
The cross-reactivity of nucleocapsid-specific CTL was exam-
ined with two serologically and genetically distinct strains
of IBV. Splenic T cells from chickens inoculated with Nd-
pTargeT lysed target cells infected with the heterologous Ar-
kansas and Mass41 strains of IBV in a dose-dependent man-
ner. Therefore, IBV-specific CTL epitopes are conserved in
the nucleocapsid proteins of various strains of IBV (Fig. 5B).
Nd-specific CTL protected chicks from acute infection.
Chickens inoculated with Nd-pTargeT or Ne-pTargeT were
challenged with the Gray strain of IBV. Chickens immunized
with Nd-pTargeT were protected from severe illness (two of six
chickens experienced mild respiratory signs of sneezing or na-
sal discharge). In contrast, all of six chicks immunized with
FIG. 4. (A) Mapping of the CTL epitope to nucleocapsid protein. CK cells were infected with Na-SFV or Nb-SFV before use as target cells for effector cells
stimulated with irradiated IBV-infected syngeneic CK cells. Lysis of target cells infected with Nb-SFV is represented by closed triangles, lysis of target cells infected
with N-SFV is represented by open squares, and lysis of target cells infected with Na-SFV is represented by open circles. (B) Further mapping of CTL epitopes to
nucleocapsid protein. CK cells were infected with IBV, N-SFV, Nc-SFV, Nd-SFV, or Ne-SFV before use as target cells for effector cells stimulated with irradiated
IBV-infected syngeneic CK cells. Lysis of target cells infected with IBV is represented by closed squares, lysis of target cells infected with N-SFV is represented by closed
triangles, lysis of target cells infected with Nd-SFV is represented by open circles, lysis of target cells infected with Nc-SFV is represented by closed circles, lysis of target
cells infected with Ne-SFV is represented by open squares, and lysis of uninfected target cells is represented by open diamonds.
FIG. 5. (A) In vivo induction of nucleocapsid-specific CTL by DNA inoculation. Splenic T cells collected from chickens inoculated with DNA recombinants were
stimulated in vitro with irradiated syngeneic CK cells infected with N-SFV before use as effector cells. Lysis of target cells infected with Nd-SFV by effector cells from
chickens inoculated with Nd-pTargeT is represented by closed triangles, lysis of target cells infected with the Gray strain of IBV by effector cells from chickens
inoculated with Nd-pTargeT is represented by closed squares, lysis of target cells infected with the Gray strain of IBV by effector cells from chickens inoculated with
Ne-pTargeT is represented by open diamonds, and lysis of target cells infected with the Gray strain of IBV by effector cells from DNA uninoculated chickens is
represented by open circles. (B) Cross-reactive CTL activity by splenic T cells from chickens inoculated with Nd-pTargeT. CK cells were infected with different strains
of IBV before use as target cells for Nd-specific effector cells stimulated in vitro with irradiated syngeneic CK cells infected with N-SFV. Lysis of target cells infected
with the Gray strain of IBV is represented by closed triangles, lysis of target cells infected with Arkansas strain of IBV is represented by open triangles, lysis of target
cells infected with the Mass41 strain of IBV is represented by open squares, and lysis of uninfected target cells is represented by open circles.
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Ne-pTargeT showed signs of severe clinical illness, such as
dyspnea, rales, lack of appetite, or ataxia, similar to those in
unimmunized chicks (Table 2).
Viral replication in lungs and kidneys from chickens inocu-
lated with pTargeT plasmids encoding Nd or Ne and chal-
lenged with the Gray strain of IBV was quantitated. The viral
burden in both lungs and kidneys of chickens immunized with
Ne-pTargeT was similar to that in the unimmunized control
chickens (Fig. 6). In contrast, compared with unvaccinated
chickens, the viral replication in chickens immunized with
Nd-pTargeT was reduced by 7 logs in lungs and to undetect-
able levels in kidneys.
DISCUSSION
This is the first description of CTL activity specific for the
nucleocapsid of IBV. The vigorous CTL response from IBV-
infected chicks was directed primarily toward the carboxyl-
terminal 120 residue (Nd). Similarly, a CTL epitope for murine
hepatitis virus was mapped to the 178-residue carboxyl termi-
nus (30). SFV vectors were used to generate target cells ex-
pressing individual polypeptides. This system was preferred
because IBV polypeptides were efficiently expressed in the
cytoplasm in the absence of structural proteins from the vector.
The presence of an IBV epitope or epitopes in the Nd region
was further substantiated through the in vivo inoculation of
DNA plasmids expressing the fragment. The second Ne frag-
ment expressing residues in the amino-terminal 75% of nu-
cleocapsid, which was not recognized by effectors from IBV-
infected chickens, did not induce CTL upon in vivo expression
using the cDNA expression plasmids.
The inoculation of DNA plasmids encoding N polypeptides
proved to be an efficient and effective means of inducing CTL.
This procedure is technically simple and results in the endog-
enous expression of antigen necessary for optimal CTL activ-
ity. As might be predicted of the highly conserved N, immunity
induced through in vivo expression of Nd was cross-reactive
with two serologically distinct strains of IBV. Immunization
with naked DNA vectors has proven to be valuable in inducing
protective immunity to other viral proteins, such as the influ-
enza virus nucleocapsid (11, 20, 22). In the present study, acute
IBV infection was reduced by 7 logs in the lungs and elimi-
nated in the kidneys of chicks inoculated with Nd DNA but not
reduced in either organ of chickens receiving DNA encoding
Ne. More complete protection of the lungs might be achieved
with direct inoculation of Nd within the respiratory tract.
In our previous study, the IBV-specific CTL response fol-
lowing infection correlated with a decrease in detectable virus
in both the lungs and kidneys. Specific IgG antibodies were not
detectable until viral loads and CTL activity declined. How-
ever, because N does not induce viral neutralizing antibody
and the Ne fragment did not protect chickens, it seems likely
that protection against acute infection was the result of the
specific CTL response. In addition, preliminary studies in
which CD81 T cells stimulated with antigen-presenting cells
endogenously expressing IBV were adoptively transferred to
chickens suggest that IBV-specific CTL can eliminate virus in
acute infection (26a).
Nucleocapsid protein closely associated with genomic RNA
plays diverse roles in the structure and replication of IBV (29).
This phosphorylated and unglycosylated protein is produced in
large quantities during replication, and its predicted amino
acid sequence is highly conserved among various IBV strains
(27, 33). Although serotyping is generally based on epitopes in
the spike protein, we now know that the nucleocapsid is highly
immunogenic at both the antibody and CTL levels (28). There-
fore, considering the continuously evolving antigenic diversity
of S1 among IBV strains, effective subunit vaccine strategies
should incorporate the IBV nucleocapsid. Future studies
should identify the peptide sequence(s) of the CTL epitope(s)
and define the apparent central role of CTL to nucleocapsid in
clearing acute IBV infection.
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